ELIQUIS indications1 |
Dose1 |
Morning* |
Night* |
DVT / PE treatment: treatment of DVT and PE in adults |
Day 1–7: |
|
|
Day 8 onwards: |
|
|
|
Prevention of recurrent DVT / PE: prevention of recurrent DVT and / or PE in adults following completion of 6 months of treatment with ELIQUIS 5 mg BD or with another anticoagulant treatment for DVT or PE |
2.5 mg BD |
|
|
The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1
* Tablets shown are not actual size.
† Short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).1
ELIQUIS indications1 |
Dose1 |
Morning* |
Night* |
Prevention of VTE in elective orthopaedic surgery: Elective knee replacement surgery |
The initial dose needs to be taken 12–24 hours after surgery |
|
|
Elective hip replacement surgery |
2.5 mg BD |
|
|
Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding the time of administration, within the 12–24 hours window after surgery, of the initial dose.1
* Tablets shown are not actual size.
No initial injections or bridging with LMWH required1
Freedom from INR monitoring1
No dietary restrictions and the choice to be taken with or without food1
If a dose is missed, take ELIQUIS immediately and then continue with twice-daily intake as before1
Liver function testing should be performed prior to initiating ELIQUIS1
Please click here to access the ELIQUIS Patient Information Leaflet.
BD = Twice Daily
DVT = Deep Vein Thrombosis
INR = International Normalised Ratio
LMWH = Low Molecular Weight Heparin
NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism
¶ Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.
Reference